Literature DB >> 19095675

Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria.

A J Goverde1, A J B van Koert, M J Eijkemans, E A H Knauff, H E Westerveld, B C J M Fauser, F J Broekmans.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with metabolic abnormalities. It is debated whether all women with PCOS should be screened for metabolic abnormalities as these may vary with PCOS phenotype, age and ethnicity. The aims of this study were to assess the prevalence of metabolic abnormalities in Dutch anovulatory PCOS women and to define criteria for metabolic screening.
METHODS: Anovulatory patients, diagnosed with PCOS according to the Rotterdam consensus criteria, underwent metabolic screening. Through stepwise multivariate analysis patient characteristics associated with metabolic syndrome (MetS) and insulin resistance (IR) were evaluated for their use as selection parameters for metabolic screening.
RESULTS: Overall, prevalence of MetS and IR was 15.9% (n = 25) and 14% (n = 22), respectively, in 157 PCOS women (age 29.0 +/- 4.8 years, BMI 26.1 +/- 6.7 kg/m(2)). Anovulatory hyperandrogenic women (with or without polycystic ovaries) had more often MetS and IR (with, 20.8 and 19.8%; without, 100 and 40%, respectively) than non-hyperandrogenic PCOS women (0 and 1.8%; P < 0.001). Waist circumference >83.5 cm along with increased free androgen index (FAI) had the most powerful association with the presence of MetS and IR (area under the receiver operating characteristic curve 0.912) and offered a reduction in the necessity of screening for metabolic derailments of about 50%.
CONCLUSIONS: The hyperandrogenic PCOS phenotypes are highly linked to the presence of MetS and IR in Dutch PCOS women. Waist circumference combined with FAI was identified as an efficient combination test to select those PCOS women who should be screened for the presence of MetS and/or IR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19095675     DOI: 10.1093/humrep/den433

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  28 in total

1.  Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology.

Authors:  Miro Šimun Alebić; Nataša Stojanović; Dinka Pavičić Baldani; Lea Smirčić Duvnjak
Journal:  Endocrine       Date:  2016-08-03       Impact factor: 3.633

2.  Renaming PCOS--a two-state solution.

Authors:  Andrea Dunaif; Bart C J M Fauser
Journal:  J Clin Endocrinol Metab       Date:  2013-09-05       Impact factor: 5.958

3.  Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep.

Authors:  Almudena Veiga-Lopez; James S Lee; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2010-06-16       Impact factor: 4.736

Review 4.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

5.  Prediction of metabolic syndrome in women with polycystic ovary syndrome.

Authors:  Fırat Ersan; Esra Arslan; Aytül Çorbacıoğlu Esmer; Serdar Aydın; Asuman Gedikbaşı; Ali Gedikbaşı; Ismet Alkış; Cemal Ark
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-09-01

6.  Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health.

Authors:  Kathleen M Brennan; Lindsay L Kroener; Gregorio D Chazenbalk; Daniel A Dumesic
Journal:  Obstet Gynecol Surv       Date:  2019-04       Impact factor: 2.347

Review 7.  The management of patients with polycystic ovary syndrome.

Authors:  Channa N Jayasena; Stephen Franks
Journal:  Nat Rev Endocrinol       Date:  2014-07-15       Impact factor: 43.330

8.  Prevalence of metabolic syndrome in women with polycystic ovary syndrome attending an infertility clinic in a tertiary care hospital in south India.

Authors:  Kavita Mandrelle; Mohan S Kamath; Dian J Bondu; Achamma Chandy; Tk Aleyamma; Korula George
Journal:  J Hum Reprod Sci       Date:  2012-01

9.  Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain.

Authors:  Jamal Golbahar; Maha Al-Ayadhi; Negalla Mohan Das; Khalid Gumaa
Journal:  Int J Womens Health       Date:  2012-05-11

10.  A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.

Authors:  Avin S Jamil; Shahla K Alalaf; Namir G Al-Tawil; Talha Al-Shawaf
Journal:  Reprod Health       Date:  2015-01-16       Impact factor: 3.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.